全文获取类型
收费全文 | 3435篇 |
免费 | 275篇 |
国内免费 | 40篇 |
专业分类
耳鼻咽喉 | 35篇 |
儿科学 | 88篇 |
妇产科学 | 87篇 |
基础医学 | 469篇 |
口腔科学 | 16篇 |
临床医学 | 335篇 |
内科学 | 864篇 |
皮肤病学 | 47篇 |
神经病学 | 291篇 |
特种医学 | 152篇 |
外科学 | 660篇 |
综合类 | 27篇 |
一般理论 | 4篇 |
预防医学 | 161篇 |
眼科学 | 73篇 |
药学 | 197篇 |
中国医学 | 6篇 |
肿瘤学 | 238篇 |
出版年
2023年 | 9篇 |
2022年 | 31篇 |
2021年 | 68篇 |
2020年 | 79篇 |
2019年 | 107篇 |
2018年 | 113篇 |
2017年 | 56篇 |
2016年 | 86篇 |
2015年 | 108篇 |
2014年 | 161篇 |
2013年 | 181篇 |
2012年 | 275篇 |
2011年 | 256篇 |
2010年 | 157篇 |
2009年 | 133篇 |
2008年 | 211篇 |
2007年 | 204篇 |
2006年 | 230篇 |
2005年 | 197篇 |
2004年 | 169篇 |
2003年 | 153篇 |
2002年 | 138篇 |
2001年 | 26篇 |
2000年 | 28篇 |
1999年 | 30篇 |
1998年 | 54篇 |
1997年 | 38篇 |
1996年 | 35篇 |
1995年 | 33篇 |
1994年 | 22篇 |
1993年 | 22篇 |
1992年 | 24篇 |
1991年 | 25篇 |
1990年 | 26篇 |
1989年 | 27篇 |
1988年 | 31篇 |
1987年 | 17篇 |
1986年 | 10篇 |
1985年 | 13篇 |
1984年 | 13篇 |
1983年 | 9篇 |
1981年 | 8篇 |
1980年 | 8篇 |
1978年 | 13篇 |
1977年 | 10篇 |
1976年 | 8篇 |
1975年 | 8篇 |
1972年 | 8篇 |
1968年 | 10篇 |
1963年 | 7篇 |
排序方式: 共有3750条查询结果,搜索用时 15 毫秒
41.
Ronald B. Moss Francois Ferre Alexandra Levine John Turner Fred C. Jensen Anne E. Daigle Steven P. Richieri Allison Truckenbrod Richard J. Trauger Dennis J. Carlo Jonas Salk 《Journal of clinical immunology》1996,16(5):266-271
Two trials of subjects inoculated with the inactivated, gp120-depleted HIV-1 Immunogen are reported. In one study, in which 19 subjects received ZDV and 8 subjects received ddI, treatment with the HIV-1 Immunogen did not affect the pharmacokinetic parameters of the antiviral drugs. In another study, 65 subjects who were previously immunized with the HIV-1 Immunogen over a mean period of 4.0 years (range, 1.2–5.4 years) received inoculations at 0 and 6 months. At some point during this 48-week study, 72% of the subjects (47/65) were receiving antiviral drug therapy. The HIV-1 DNA load in CD4 cells and CD4 percentage were found to be stable over the 48-week period. Delayed-type hypersensitivity to HIV-1 antigens increased after two inoculations with the HIV-1 Immunogen. In these two trials, no serious treatment-related adverse events were documented in the subjects. The two studies presented herein are the first to suggest that an immune-based therapy such as the HIV-1 Immunogen can be combined safely with antiviral drugs, supporting further study to evaluate the clinical utility of this approach. 相似文献
42.
Claude P. Muller Daniela Handtmann Nicolaas H. C. Brons Martin Weinmann Karl-Heinz Wiesmü ller Gü nther Spahn Michael Wiesneth Francois Schneider Gü nther Jung 《Virus research》1993,30(3):271-280
The measles virus induces a life-long immune response associated with antibodies specific for the fusion protein. To map the linear immunodominant recognition sites of the fusion (F) protein of the measles virus, we have reacted a complete set of 108 overlapping pentadecapeptides with purified IgG obtained from donor sera with elevated anti-measles titers. The antibodies recognized about 20% of the peptides and generated a characteristic binding pattern, defining about 6 or 7 distinctive regions (31–75; 111–145; 151–165; 191–215; 271–320; 421–440; 481–530) which include the major hydrophobic segment (111–145) of the intersubunit region and the C-terminal Cys-cluster region. The binding sites were located in close proximity of the few experimentally defined T cell epitopes. This pairing of T and B cell epitopes was corroborated by computer-assisted T cell prediction. The significance of a non-random association of T and B cell epitopes for processing and presentation is discussed. It is speculated that in long-term immunity against measles (F protein), B cells of the same sIg specificity play an important role both as antigen presenting cells and as antibody producing cells. In contrast to human sera from late convalescent donors, mouse and rabbit MV antisera with high neutralizing titers as well as neutralizing MV-F specific monoclonal antibodies did not react with the peptides. 相似文献
43.
Julien Guihaire Serena D'Avino Francois Stephan Martin Kloeckner Ngoc Tram To Agathe Potier Maïra Gaillard Ramzi Ramadan Jean‐Luc Taupin Jerome Le Pavec Philippe Deleuze 《Clinical transplantation》2021,35(1):e14146
Antihuman leukocyte antigen (HLA) antibodies restrict the access to cardiac allografts. Desensitization therapy is a major challenge in patients with cardiogenic shock waiting for urgent heart transplantation (HT). We retrospectively reviewed six patients (mean age of 37.5 years [16–70]) who underwent plasmapheresis (PP) under extracorporeal membrane oxygenation (ECMO) before transplant between January 2017 and September 2018. The average duration of follow‐up was 25 months [20–32]. Mean fluorescence intensity (MFI) of HLA‐specific antibodies was reported as follows: score 4 for MFI < 1000, score 6 for 1000 < MFI < 3000 and score 8 for MFI > 3000. The mean duration of ECMO support was 29 days [1–74] and 6.8 [1–29] PP sessions were performed per patient before transplant. The mean number of HLA‐specific antibodies before HT was 9.6 for score 6 [4–13] and 5.8 for score 8 [1–12]. Four patients had major complications after transplantation (2 hemorrhagic shocks, 5 infectious events). Mean MFI reduction rate was 94% [79–100] for Class I and 44.2% for Class II [0–83]. Hospital survival was 100%, and early antibody‐mediated rejection was diagnosed in one patient at 7 days after HT. Plasmapheresis under ECMO support was associated with favorable early outcomes in highly sensitized candidates for urgent heart transplantation. 相似文献
44.
45.
类风湿关节炎(RA)在中医学中属于“痹病”范畴,是临床中常见的难治性疾病,且呈年轻化趋势,迁延难愈。目前现代医学对RA的发病病因及机制尚不完全清楚。《素问·痹论》提出风寒湿三邪致痹,还有学者提出痰瘀致痹、肝肾亏虚等观点。李彦民主任医师根据多年临床经验提出RA的病机关键是络脉痹阻,其病机特点是虚实夹杂,临床辨证分为寒湿阻络型、湿热蕴结型、痰瘀互结型、气血两虚型、肝肾亏虚型等五型。分别采用祛邪通络和补虚通络等不同治则,辨证施法。李老师善用川乌、鸡血藤以及乌梢蛇等药以通络止痛,并主张辨证用药,内外兼治,多取良效。临床采用经验方仙龙汤,配合外用舒筋活络洗剂,且取得理想疗效。 相似文献
46.
47.
Emilie Savoye Camille Legeai Julien Branchereau Samuel Gay Bruno Riou Francois Gaudez Benoit Veber Franck Bruyere Gaelle Cheisson Thomas Kerforne Lionel Badet Olivier Bastien Corinne Antoine and the cDCD National Steering Committee 《American journal of transplantation》2021,21(7):2424-2436
Controlled donation after circulatory death (cDCD) is used for “extended criteria” donors with poorer kidney transplant outcomes. The French cDCD program started in 2015 and is characterized by normothermic regional perfusion, hypothermic machine perfusion, and short cold ischemia time. We compared the outcomes of kidney transplantation from cDCD and brain-dead (DBD) donors, matching cDCD and DBD kidney transplants by propensity scoring for donor and recipient characteristics. The matching process retained 442 of 499 cDCD and 809 of 6185 DBD transplantations. The DGF rate was 20% in cDCD recipients compared with 28% in DBD recipients (adjusted relative risk [aRR], 1.43; 95% confidence interval [CI] 1.12–1.82). When DBD transplants were ranked by cold ischemia time and machine perfusion use and compared with cDCD transplants, the aRR of DGF was higher for DBD transplants without machine perfusion, regardless of the cold ischemia time (aRR with cold ischemia time <18 h, 1.57; 95% CI 1.20–2.03, vs aRR with cold ischemia time ≥18 h, 1.79; 95% CI 1.31–2.44). The 1-year graft survival rate was similar in both groups. Early outcome was better for kidney transplants from cDCD than from matched DBD transplants with this French protocol. 相似文献
48.
Edrophonium administered in divided doses has been reported to accelerate antagonism of neuromuscular blockade, i.e., a "priming" effect. Since measured onset times can be affected by the type of stimulation used, this effect was studied using both train-of-four (TOF) and single twitch (ST) stimulation. During thiopentone-nitrous oxide-enflurane anaesthesia 20 adults were given atracurium 0.5 mg.kg-1. Both ulnar nerves were stimulated with TOF every 12 sec until one per cent recovery of first twitch (T1). At this time, ST stimulation was applied to one arm, selected at random. When the mean value of T1 and ST reached ten per cent of control, edrophonium, 1 mg.kg-1, preceded by atropine was given either as a single dose, or in two doses consisting of 0.2 mg.kg-1 followed by 0.8 mg.kg-1 three minutes later. No statistically significant differences were observed between T1 and ST for the next ten minutes, whether edrophonium had been given in single or divided doses. Giving edrophonium in divided doses did not improve recovery significantly, measured with either T1, ST or train-of-four ratio (T4/T1). Five minutes after the first administration of edrophonium, T1 was (mean +/- SEM) 86 +/- 3 and 86 +/- 2 per cent control in the single and divided dose groups respectively. Corresponding values for ST were 89 +/- 1 and 89 +/- 2 per cent (NS), and for TOF, 49 +/- 3 and 57 +/- 3 per cent (NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
49.
Cummings KM Kelly J Sciandra R Deloughry T Francois F 《American journal of health promotion : AJHP》1990,4(6):429-434
Abstract This paper presents the results of a follow-up evaluation conducted to assess the impact of a community-wide stop smoking contest conducted in Buffalo, New York in January 1988. The contest challenged smokers to make a pledge to quit jar 30 days to have a chance to win $1,000 cash, a vacation trip, or other prizes. Finalists were randomly selected and chemically tested to verify abstinence. Telephone follow-up interviews were conducted on a sample of 411 contestants six weeks and eight months after the quit date. A total of 2,565 smokers enrolled in the contest. Compared to smokers in the general population, contestants were more likely to be female, white, under age 40, and smoke 25 or more cigarettes daily. Over 90 percent of contestants attempted to stop smoking, 51 percent quit jar the 3D-day contest period, and 32 percent were not smoking after eight months. 相似文献
50.
Martin Kolev Tara Barbour Scott Baver Cedric Francois Pascal Deschatelets 《Immunological reviews》2023,313(1):358-375
C3 is a key complement protein, located at the nexus of all complement activation pathways. Extracellular, tissue, cell-derived, and intracellular C3 plays critical roles in the immune response that is dysregulated in many diseases, making it an attractive therapeutic target. However, challenges such as very high concentration in blood, increased acute expression, and the elevated risk of infections have historically posed significant challenges in the development of C3-targeted therapeutics. This is further complicated because C3 activation fragments and their receptors trigger a complex network of downstream effects; therefore, a clear understanding of these is needed to provide context for a better understanding of the mechanism of action (MoA) of C3 inhibitors, such as pegcetacoplan. Because of C3's differential upstream position to C5 in the complement cascade, there are mechanistic differences between pegcetacoplan and eculizumab that determine their efficacy in patients with paroxysmal nocturnal hemoglobinuria. In this review, we compare the MoA of pegcetacoplan and eculizumab in paroxysmal nocturnal hemoglobinuria and discuss the complement-mediated disease that might be amenable to C3 inhibition. We further discuss the current state and outlook for C3-targeted therapeutics and provide our perspective on which diseases might be the next success stories in the C3 therapeutics journey. 相似文献